Press Releases

Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
June 09, 2021

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
May 06, 2021

Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
April 29, 2021

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical’s Lead Drug, CRV431
March 23, 2021

Hepion Pharmaceuticals Announces Presentation and Panel Participation at the Benzinga Global Biotech Small Cap Conference
March 22, 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POWR™ at NASH-TAG 2021
March 11, 2021

Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering
February 18, 2021

Hepion Pharmaceuticals Announces Pricing of Public Offering
February 16, 2021

Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
February 12, 2021

Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
February 10, 2021